Page 1284 - Williams Hematology ( PDFDrive )

1258 Part IX: Lymphocytes and Plasma Cells Chapter 81: Hematologic Manifestations of Acquired Immunodeficiency Syndrome 1259

260. Koduri PR, Kumapley R, Valladares J, et al: Chronic pure red cell aplasia caused by par- 275. Servais J, Nkoghe D, Schmit JC, et al: HIV-associated hematologic disorders are cor-
vovirus B19 in AIDS: Use of intravenous immunoglobulin—A report of eight patients. related with plasma viral load and improve under highly active antiretroviral therapy.
Am J Hematol 61:16–20, 1999. J Acquir Immune Defic Syndr 28:221–225, 2001.
261. Moyle G, Sawyer W, Law M, et al: Changes in hematologic parameters and efficacy of 276. Ballem PJ, Belzberg A, Devine DV, et al: Kinetic studies of the mechanism of throm-
thymidine analogue-based, highly active antiretroviral therapy: A meta-analysis of six bocytopenia in patients with human immunodeficiency virus infection. N Engl J Med
prospective, randomized, comparative studies. Clin Ther 26:92–97, 2004. 327:1779–1784, 1992.
262. Fischl M, Galpin JE, Levine JD, et al: Recombinant human erythropoietin for patients 277. Zucker-Franklin D, Cao YZ: Megakaryocytes of human immunodeficiency virus-
with AIDS treated with zidovudine. N Engl J Med 322:1488–1493, 1990. infected individuals express viral RNA. Proc Natl Acad Sci U S A 86:5595–5599, 1989.
263. Henry DH, Beall GN, Benson CA, et al: Recombinant human erythropoietin in the 278. Zidovudine for the treatment of thrombocytopenia associated with human immunode-
treatment of anemia associated with human immunodeficiency virus (HIV) infection ficiency virus (HIV). A prospective study. The Swiss Group for Clinical Studies on the
and zidovudine therapy. Overview of four clinical trials. Ann Intern Med 117:739–748, Acquired Immunodeficiency Syndrome (AIDS). Ann Intern Med 109:718–721, 1988.
1992. 279. Arranz Caso JA, Sanchez Mingo C, Garcia Tena J: Effect of highly active antiretrovi-
264. Marti-Carvajal AJ, Sola I, Pena-Marti GE, et al: Treatment for anemia in people with ral therapy on thrombocytopenia in patients with HIV infection. N Engl J Med 341:
AIDS. Cochrane Database Syst Rev (10):CD004776, 2011. 1239–1240, 1999.
265. Gervasoni C, Ridolfo AL, Vaccarezza M, et al: Thrombotic microangiopathy in patients 280. Carbonara S, Fiorentino G, Serio G, et al: Response of severe HIV-associated thrombo-
with acquired immunodeficiency syndrome before and during the era of introduction cytopenia to highly active antiretroviral therapy including protease inhibitors. J Infect
of highly active antiretroviral therapy. Clin Infect Dis 35:1534–1540, 2002. 42:251–256, 2001.
266. Becker S, Fusco G, Fusco J, et al: HIV-associated thrombotic microangiopathy in the 281. Rosenblum M, Deeks SG, van der Laan M, et al: The risk of virologic failure decreases
era of highly active antiretroviral therapy: An observational study. Clin Infect Dis 39 with duration of HIV suppression, at greater than 50% adherence to antiretroviral ther-
Suppl 5:S267–S275, 2004. apy. PLoS One 4:e7196, 2009.
267. Benjamin M, Terrell DR, Vesely SK, et al: Frequency and significance of HIV infection 282. Scaradavou A, Woo B, Woloski BM, et al: Intravenous anti-D treatment of immune
among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis thrombocytopenic purpura: Experience in 272 patients. Blood 89:2689–2700, 1997.
48:1129–1137, 2009. 283. Scaradavou A, Cunningham-Rundles S, Ho JL, et al: Superior effect of intravenous
268. Hart D, Sayer R, Miller R, et al: Human immunodeficiency virus associated throm- anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia:
botic thrombocytopenic purpura—Favourable outcome with plasma exchange and Results of a small, randomized prospective comparison. Am J Hematol 82:335–341,
prompt initiation of highly active antiretroviral therapy. Br J Haematol 153:515–519, 2007.
2011. 284. Oksenhendler E, Bierling P, Chevret S, et al: Splenectomy is safe and effective in human
269. Malak S, Wolf M, Millot GA, et al: Human immunodeficiency virus-associated immunodeficiency virus-related immune thrombocytopenia. Blood 82:29–32, 1993.
thrombotic microangiopathies: Clinical characteristics and outcome according to 285. Aslam MI, Cardile AP, Crawford GE: Use of peptide thrombopoietin receptor agonist
ADAMTS13 activity. Scand J Immunol 68:337–344, 2008. romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia. J Int
270. Sogaard OS, Lohse N, Ostergaard L, et al: Morbidity and risk of subsequent diagnosis Assoc Provid AIDS Care 13:22–23, 2014.
of HIV: A population based case control study identifying indicator diseases for HIV 286. Quach H, Lee LY, Smith B, et al: Successful use of eltrombopag without splenec-
infection. PLoS One 7:e32538, 2012. tomy in refractory HIV-related immune reconstitution thrombocytopenia. AIDS 26:
271. Ambler KL, Vickars LM, Leger CS, et al: Clinical Features, Treatment, and Outcome 1977–1979, 2012.
of HIV-Associated Immune Thrombocytopenia in the HAART Era. Adv Hematol 287. Firnhaber C, Smeaton L, Saukila N, et al: Comparisons of anemia, thrombocytope-
2012:910954, 2012. nia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the
272. Vannappagari V, Nkhoma ET, Atashili J, et al: Prevalence, severity, and duration of Americas. Int J Infect Dis 14:e1088–e1092, 2010.
thrombocytopenia among HIV patients in the era of highly active antiretroviral ther- 288. Levine AM, Karim R, Mack W, et al: Neutropenia in human immunodeficiency
apy. Platelets 22:611–618, 2011. virus infection: Data from the women’s interagency HIV study. Arch Intern Med 166:
273. Ghosn J, Persoz A, Zitoun Y, et al: Thrombocytopenia during primary HIV-1 infection 405–410, 2006.
predicts the risk of recurrence during chronic infection. J Acquir Immune Defic Syndr 289. Moore DA, Benepal T, Portsmouth S, et al: Etiology and natural history of neutrope-
60:e112–e114, 2012. nia in human immunodeficiency virus disease: A prospective study. Clin Infect Dis 32:
274. Marks KM, Clarke RM, Bussel JB, et al: Risk factors for thrombocytopenia in HIV- 469–475, 2001.
infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr 290. Zhu NY, Legatt DF, Turner AR: Agranulocytosis after consumption of cocaine adulter-
52:595–599, 2009. ated with levamisole. Ann Intern Med 150:287–289, 2009.

Kaushansky_chapter 81_p1239-1260.indd 1259 9/21/15 11:19 AM